Several clinical trials have shown that gefitinib, erlotinib, and afatinib showed superiority in efficacy to platinum-based chemotherapy as a standard of care for treatment-naïve NSCLC patients harboring EGFR mutations [2,3,4,5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.